| Prev Close | 5.82 |
| Open | 5.90 |
| Day Low/High | 5.82 / 5.95 |
| 52 Wk Low/High | 4.14 / 11.52 |
| Volume | 69.22K |
| Avg Volume | 448.40K |
RedHill Biopharma Ltd. (RDHL)
5.94
0.12
2.10
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 35.27M |
| Market Cap | 247.59M |
| EPS | -1.40 |
| P/E Ratio | 69.45 |
| Div & Yield | N.A. (N.A) |
Latest News
Veeva and RedHill: 2 Stocks to Consider as They Team Up to Battle Covid-19
RedHill Biopharma has adopted 'Veeva Vault CDMS', Veeva's modern cloud platform.
Let's Head Overseas for a Trio of Undervalued Healthcare Plays
These promising companies look like good names for patient buy-and-hold investors.
2 Picks, 2 Pans Among Small-Cap Biotechs Laboring in the Covid-19 Fields
Quotient Limited and Redhill Biopharma could deliver for shareholders, while Novavax Inc. and Inovio Pharmaceuticals may not in the end.
3 Small-Caps That Look Like Bargains at Current Trading Levels
The trio consists of BioDelivery Sciences International, Beazer Homes USA and Redhill Biopharma.
2 Key 'Rules' When Investing in Biotech Stocks
Remembering these 'rules of the road' is vital in this highly volatile space.
How I Invest In Biotech Stocks
Here's two 'rules of the road' when investing in this highly volatile space.
Celgene Down After Pulling Plug on Crohn's Disease Drug Study -- Biotech Movers
The Summit, N.J.-based firm said Thursday that it was discontinuing the GED-0301 (mongersen) Phase 3 Revolve study in Crohn's disease and the extension trial.
3 Small Biotechs That Still Have Upside
Companies developing drugs for cancer, eye problems and pets -- offer untapped value.
One Small Pharma Stock Has Big Potential
Redhill has some promising drugs in its pipeline, and is well funded.
5 Small-Cap Biotechs With Big Potential
These 5 stocks all have positive catalysts on the horizon.
5 Small-Cap Biotechs With Big Potential
These 5 stocks all have positive catalysts on the horizon.
